Pricing

TRACON Pharmaceuticals Inc (TCON)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Charles P. Theuer
Employees:
20
4350 LA JOLLA VILLAGE DRIVE, SUITE 800, San Diego, CA, 92122
858-550-0780
Stock Split History
DateRatio
2019-11-08 1:10
2024-04-10 1:20
TRACON Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody. TRC102, a small molecule that is in Phase II clinical trial for the. treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and gliob
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available